title: Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.
abstract: This retrospective study compared efficacy and safety of fludarabine combined with intermediate-dose cytarabine (FA regimen) versus high-dose cytarabine (HiDAC regimen) as consolidation therapy in acute myeloid leukemia (AML) patients who achieved complete remission. Disease-free survival (DFS) and overall survival (OS) based on age (≥ 60, <60 years) and cytogenetics were evaluated from data between January 2005 and March 2013. Total 82 patients (FA, n = 45; HiDAC, n = 37; 14-65 years) were evaluated. Five-year DFS was 32.0% and 36.2% for FA and HiDAC groups, respectively (P = 0.729), and 5-year OS was 39.5% and 47.8% (P = 0.568), respectively. Among older patients (≥ 60 years), 3-year DFS was 26.0% for FA group and 12.5% for HiDAC group (P = 0.032), and 3-year OS was 34.6% and 12.5%, respectively (P = 0.026). In FA group, hematological toxicities were significantly lower. FA regimen was as effective as HiDAC regimen in patients with good/intermediate cytogenetics and significantly improved DFS and OS in older patients.
authors.affiliation: From the Department of Hematology, Tongji Hospital, Tongji University School of Medicine (WZ, YD, HW, YC, HL, CC, JF, AL); and Department of Hematology, Zhongshan Hospital, Fudan University (WW, SZ), Shanghai, China.
authors.forename: Wenjun
authors.initials: W
authors.lastname: Zhang
authors.forename: Yi
authors.initials: Y
authors.lastname: Ding
authors.forename: Hao
authors.initials: H
authors.lastname: Wu
authors.forename: Yuhua
authors.initials: Y
authors.lastname: Chen
authors.forename: Huina
authors.initials: H
authors.lastname: Lu
authors.forename: Chunying
authors.initials: C
authors.lastname: Chen
authors.forename: Jianfei
authors.initials: J
authors.lastname: Fu
authors.forename: Weiguang
authors.initials: W
authors.lastname: Wang
authors.forename: Aibin
authors.initials: A
authors.lastname: Liang
authors.forename: Shanhua
authors.initials: S
authors.lastname: Zou
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols; D060830:Consolidation Chemotherapy; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D055815:Young Adult
chemical_list: D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D014740:Vidarabine; C024352:fludarabine